KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Net Margin (2016 - 2025)

Historic Net Margin for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to 296.76%.

  • Nektar Therapeutics' Net Margin fell 1431500.0% to 296.76% in Q3 2025 from the same period last year, while for Sep 2025 it was 181.12%, marking a year-over-year decrease of 4200.0%. This contributed to the annual value of 120.89% for FY2024, which is 1854200.0% up from last year.
  • As of Q3 2025, Nektar Therapeutics' Net Margin stood at 296.76%, which was down 1431500.0% from 350.85% recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Net Margin ranged from a high of 24.8% in Q4 2024 and a low of 736.94% during Q2 2022
  • Its 5-year average for Net Margin is 346.71%, with a median of 302.43% in 2022.
  • Its Net Margin has fluctuated over the past 5 years, first plummeted by -2938800bps in 2022, then skyrocketed by 4875500bps in 2023.
  • Quarter analysis of 5 years shows Nektar Therapeutics' Net Margin stood at 587.42% in 2021, then skyrocketed by 49bps to 302.43% in 2022, then surged by 42bps to 176.17% in 2023, then surged by 114bps to 24.8% in 2024, then crashed by -1297bps to 296.76% in 2025.
  • Its Net Margin stands at 296.76% for Q3 2025, versus 350.85% for Q2 2025 and 443.8% for Q1 2025.